DealsApr 22, 2026, 07:31 AM
Rafael Holdings Subsidiary Licenses MIT Patent for Alzheimer's
AI Summary
Rafael Holdings, Inc. announced that its subsidiary, Cyclo Therapeutics, LLC, has entered into an exclusive licensing agreement with Massachusetts Institute of Technology (MIT). This agreement covers U.S. Patent No. 12285440, which pertains to the use of cyclodextrins in treating Alzheimer's Disease patients who carry an ApoE4 genetic mutation. This deal could enhance Cyclo Therapeutics' pipeline in neurodegenerative diseases.
Key Highlights
- Cyclo Therapeutics, a Rafael Holdings subsidiary, secured an exclusive license.
- Agreement with MIT covers U.S. Patent No. 12285440.
- Patent relates to cyclodextrins for Alzheimer's patients with ApoE4 mutation.